CN105705148B - 使用普那布林和紫杉烷的组合的癌症疗法 - Google Patents

使用普那布林和紫杉烷的组合的癌症疗法 Download PDF

Info

Publication number
CN105705148B
CN105705148B CN201380080185.5A CN201380080185A CN105705148B CN 105705148 B CN105705148 B CN 105705148B CN 201380080185 A CN201380080185 A CN 201380080185A CN 105705148 B CN105705148 B CN 105705148B
Authority
CN
China
Prior art keywords
docetaxel
plinabulin
group
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380080185.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105705148A (zh
Inventor
黄岚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52812462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105705148(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of CN105705148A publication Critical patent/CN105705148A/zh
Application granted granted Critical
Publication of CN105705148B publication Critical patent/CN105705148B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380080185.5A 2013-10-11 2013-10-11 使用普那布林和紫杉烷的组合的癌症疗法 Active CN105705148B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/085075 WO2015051543A1 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Publications (2)

Publication Number Publication Date
CN105705148A CN105705148A (zh) 2016-06-22
CN105705148B true CN105705148B (zh) 2021-03-23

Family

ID=52812462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380080185.5A Active CN105705148B (zh) 2013-10-11 2013-10-11 使用普那布林和紫杉烷的组合的癌症疗法

Country Status (18)

Country Link
US (2) US10596169B2 (enExample)
EP (1) EP3076972B1 (enExample)
JP (1) JP6411523B2 (enExample)
KR (1) KR102225371B1 (enExample)
CN (1) CN105705148B (enExample)
AU (1) AU2013402794B2 (enExample)
BR (1) BR112016007946A2 (enExample)
CA (1) CA2926771C (enExample)
DK (1) DK3076972T3 (enExample)
ES (1) ES2902665T3 (enExample)
IL (1) IL244984B (enExample)
MX (1) MX384751B (enExample)
MY (1) MY185650A (enExample)
NZ (1) NZ719049A (enExample)
RU (1) RU2662298C2 (enExample)
SG (1) SG11201602637QA (enExample)
WO (1) WO2015051543A1 (enExample)
ZA (1) ZA201602380B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394865B (es) * 2015-02-12 2025-03-24 Beyondspring Pharmaceuticals Inc Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
WO2016144636A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
EP3334726B1 (en) * 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) * 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals, Inc. composições de plinabulina e seu uso
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
WO2019147615A1 (en) * 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
BR112020015758A2 (pt) * 2018-02-01 2020-12-08 Beyondspring Pharmaceuticals, Inc. Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
AU2019378779A1 (en) * 2018-11-14 2021-06-03 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
CN113613654B (zh) * 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
AU2003302721B2 (en) 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BRPI0506655A (pt) * 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CA2905418C (en) 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity

Also Published As

Publication number Publication date
MX384751B (es) 2025-03-14
WO2015051543A1 (en) 2015-04-16
CA2926771C (en) 2022-07-05
EP3076972A4 (en) 2017-12-20
AU2013402794B2 (en) 2020-02-27
IL244984A0 (en) 2016-05-31
NZ719049A (en) 2020-06-26
KR20160078987A (ko) 2016-07-05
RU2662298C2 (ru) 2018-07-25
WO2015051543A8 (en) 2016-04-21
US20200281921A1 (en) 2020-09-10
EP3076972B1 (en) 2021-10-06
RU2016112608A (ru) 2017-11-16
AU2013402794A1 (en) 2016-05-12
ES2902665T3 (es) 2022-03-29
US20160250209A1 (en) 2016-09-01
MY185650A (en) 2021-05-27
SG11201602637QA (en) 2016-05-30
DK3076972T3 (da) 2022-01-03
KR102225371B1 (ko) 2021-03-10
US10596169B2 (en) 2020-03-24
CA2926771A1 (en) 2015-04-16
ZA201602380B (en) 2022-05-25
MX2016004441A (es) 2016-10-28
JP2016536352A (ja) 2016-11-24
IL244984B (en) 2022-05-01
BR112016007946A2 (pt) 2017-09-12
CN105705148A (zh) 2016-06-22
EP3076972A1 (en) 2016-10-12
JP6411523B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
KR102225371B1 (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
JP2012500180A5 (enExample)
AU2018217120A1 (en) Method of reducing neutropenia
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
KR20160135230A (ko) 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도
WO2011109755A1 (en) Combination therapy for small cell lung cancer
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
CA3051828A1 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
US20200129473A1 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
KR101978108B1 (ko) 암 세포의 대사 특이성에 기초하는 신규 항 악성 종양제
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
KR20240046527A (ko) 암치료를 위한 신규 경구용 약학적 조성물
JP2018199726A (ja) プリナブリン及びタキサンの組合せがん治療
EP4364742A1 (en) Pharmaceutical composition for treating solid tumors
WO2025166537A1 (en) Methods of treatment using an ezh2 modulator
RU2818453C2 (ru) Комбинация ингибитора mcl-1 и мидостаурина, ее применения и фармацевтические композиции
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant